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Abstract
Background: An important etiological hypothesis about depression is stress has neurotoxic effects that damage the
hippocampal cells. Corticotropin-releasing hormone (CRH) regulates brain-derived neurotrophic factor (BDNF) expression
through influencing cAMP and Ca2+ signaling pathways during the course. The aim of this study is to examine the single
and combined effects of CRH receptor 1 (CRHR1) and BDNF genes in recurrent major depressive disorder (MDD).
Methodology/Principal Finding: The sample consists of 181 patients with recurrent MDD and 186 healthy controls.
Whether genetic variations interaction between CRHR1 and BDNF genes might be associated with increased susceptibility
to recurrent MDD was studied by using a gene-based association analysis of single-nucleotide polymorphisms (SNPs).
CRHR1 gene (rs1876828, rs242939 and rs242941) and BDNF gene (rs6265) were identified in the samples of patients
diagnosed with recurrent MDD and matched controls. Allelic association between CRHR1 rs242939 and recurrent MDD was
found in our sample (allelic: p=0.018, genotypic: p=0.022) with an Odds Ratio 0.454 (95% CI 0.266–0.775). A global test of
these four haplotypes showed a significant difference between recurrent MDD group and control group (chi-2=13.117,
df=3, P=0.016. Furthermore, BDNF and CRHR1 interactions were found in the significant 2-locus, gene–gene interaction
models (p=0.05) using a generalized multifactor dimensionality reduction (GMDR) method.
Conclusion: Our results suggest that an interaction between CRHR1 and BDNF genes constitutes susceptibility to recurrent
MDD.
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Introduction
Major depressive disorder (MDD) is frequently characterized by
periodic depressed mood and the loss of interest, often with
thoughts of death. Severe forms of depression affect 2–5% of the
population worldwide, and up to 20% suffer from milder forms of
the disease, and depression is also associated with high rates of
relapse, recurrent, disability, and death [1]. Despite the high
morbidity and mortality associated with MDD, the etiology and
pathophysiology of MDD have not been precisely defined. Family,
twin, and adoption studies provide strong evidence for an
important genetic component [2]. To uncover the genetic
mechanisms underlying susceptibility to depression and related
traits may also prove a successful way to understand better the
etiological features of MDD [3].
Stress response and neurotoxic effects are important etiological
hypotheses about depression. Neurotoxins (possibly related to
excessive corticotrophin activity and/or to the inflammatory
effects of cytokines) damage or kill hippocampal cells, leading to
many depressive symptoms. A deficient function of neuroprotec-
tive peptides, for example, brain-derived neurotrophic factor
(BDNF), which reduces serum BDNF in MDD [4]. Hypothalamic-
pituitary-adrenal (HPA) axis dysregulation and reduced neuro-
plasticity in depression are consistent with the assumption that
BDNF is a stress-responsive intercellular messenger modifying
HPA axis activity [5]. As a major mediator of the stress response in
the central nervous system,corticotropin releasing hormone (CRH)
affects other central processes, such as learning and memory,
synaptic plasticity, and neuroprotection [6]. Abnormal CRH
neurotransmission and receptor signal transduction has been
proposed to be a critical mechanism for stress pathophysiology
that leads to major depression [7]. Bayatti et al considered that
CRH regulates BDNF expression through influencing cAMP and
Ca2+ signaling pathways [8].
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are two primary receptors subtypes in the central nervous system
CRHR1 and CRHR2 [9]. CRH has a higher affinity for CRHR1
than for CRHR2, and in the brain, CRHR1 is expressed at high
levels in the hippocampus, cortex and cerebellum [10]. CRH
binding to CRHR1 typically activates adenylate cyclase (AC),
which leads to increased intracellular concentrations of cAMP and
activation of protein kinase A. One putative target is the BDNF,
whose expression is controlled by cAMP-elevating agents in
neurons [11]. In addition to its role as a classical target-derived
growth factor during neuronal development, BDNF is an essential
autocrine factor, released and acting locally after neuronal
depolarization [12].
As CRHR1 may play a significant role in the etiology and
treatment of depression, it is suggested that CRHR1 is a relevant
candidate gene for MDD. In Mexican-Americans population, a
significant association has been reported between CRHR1 and a
greater response to selective serotonin reuptake inhibitors (SSRI)
treatment in highly anxious MDD patients [13], but the
distribution of the MDD was similar to the healthy controls. We
have already reported that rs242939 AG carriers of CRHR1 have
a greater risk of MDD in Han Chinese population, which showed
marked geographical and ethnic variability of MDD [14], and that
CRHR1 gene is likely to be involved in the antidepressant
response in MDD [15]. Ressler et al reported a gene by gene-by-
environment (G6G6E) interaction between the CRHR1, the 5-
HTTLPR polymorphisms, and childhood abuse on depressive
symptoms [16].
The BDNF gene rs6265 (G196A) polymorphism is functionally
relevant [17]. The expression of BDNF is modified by antide-
pressant treatment [18]. Most association studies of BDNF
polymorphism and depression related traits have yielded negative
results. However, several lines of evidence suggest that lower active
A allele of BDNF rs6265 polymorphism is associated with the
features associated with the risk of depression [19].
Addressing gene-gene interactions is crucial to characterizing a
trait involving complex disease-related mechanisms, particularly
when each involved feature only demonstrates a minor marginal
effect [20]. Gene-gene interactions have been hypothesized to
contribute to the etiology of depression [21]. Considering the
higher heritability of recurrent depression than single episode
depression, analyzing these two groups separately was much more
important [22]. On the basis of a large number of studies, we
undertook a case-control study to examine the combined effects of
CRHR1 and BDNF genes on recurrent MDD in Chinese Han
people.
Results
In our total sample size (n=367), power analysis for case-
control samples was carried out by G* Power program, the sample
size had a post-hoc power of 0.99 to detect an effect size of 0.5
(moderate) at the 0.05 significance level (2-tailed). Genotype
distributions for the four SNPs were in Hardy–Weinberg
equilibrium. The results from single marker analysis of these four
SNPs are presented in Table 1. An allelic association between
CRHR1 rs242939 and recurrent MDD was found in our sample
(allelic: p=0.018, genotypic: p=0.022) with an Odds Ratio of
0.454 (95% CI 0.266–0.775), which is reflected by a significant
increase of the G-allele of 242939 in the recurrent MDD group
than the control group. CRHR1 (rs1876828, rs242941) and
BDNF (rs6265) alleles were found no association with the risk of
recurrent MDD in present sample (p=0.1952, 0.0822, 0.4078
respectively).
Haplotype frequencies in the MDD group and in the control
group were estimated using the EM algorithm embedded. Four
common haplotypes (G-A-G, G-A-T, A-A-T, G-G-T respectively
the SNPs of rs1876828, rs242939, rs242941), were found to
present in the sample. Using chi-2 test, a global test of these four
haplotypes showed a significant different distribution between the
recurrent MDD group and the control group (chi-2=13.104,
df=3, P=0.016) (Table 2).
To assess further combined effects of these genetic variants on
recurrent MDD risk by using GMDR analysis. The GMDR
software provides a number of output parameters, including CV
consistency, the testing balanced accuracy, and empirical p values,
to assess each selected interaction. The CV consistency score is a
measure of the degree of consistency with which the selected
interaction is identified as the best model among all possibilities
considered. Furthermore, the testing balanced accuracy is a
measure of the degree to which the interaction accurately predicts
case–control status with scores between 0.50 (indicating that the
model predicts no better than chance) and 1.00 (indicating perfect
Table 1. Allele and genotype distribution of CRHR1 and BDNF polymorphisms of recurrent MDD patients and controls.
Gene SNP ID
a Position Genotype P Allele P Odds Ratio
(95%CI)
AA AG GG A G
BDND rs6265 chr11:27679916 MDD 39 87 55 0.4301 165 197 0.4078 1.134
CON 37 84 65 158 214 (0.847–1.519)
CRHR1 rs1876828 chr17:43911525 MDD 149 30 2 0.3126 328 34 0.1952 1.395
CON 143 39 4 325 47 (0.874–2.226)
rs242939 chr17:43895579 MDD 139 40 2 0.022
b 318 44 0.018
b 0.454
CON 166 18 2 350 22 (0.266–0.775)
GG GT TT G T
rs242941 chr17:43892520 MDD 124 47 10 0.126 298 64 0.0822 1.421
CON 115 58 13 285 87 (0.990–2.040)
aSNP, single nucleotide polymorphism.
bBold numerals p-values after Bonferroni correction.
doi:10.1371/journal.pone.0028733.t001
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rs242939 CRHR1 had a CV consistency of 10 and p value of
0.05 after Bonferroni correction, which was considered as the best
of two factors. The interaction between BDNF (rs6265) and
CRHR1 (rs1876828, rs242939, rs242941) had a CV consistency of
10 and p value of 0.021, which was considered as the best of four
factors, indicating a potential gene–gene interaction between
BDNF and CRHR1. However, after Bonferroni correction, the 4-
locus model no longer significant. Overall, the 2-locus model had
the highest level of testing accuracy (59.16%) and showed good
CV consistency (10/10) (Table 3). Therefore, we chose the 2-locus
model as the best GMDR model. Furthermore, the significant
interactions among the above 2-locus models were confirmed by
logistic regression models (p=0.013).
Discussion
In the present study, we evaluated the individual and the joint
effects of four polymorphisms in two candidate genes on recurrent
MDD in a Chinese population. The results suggested that the
CRHR1 gene not only has a major effect, but also a combined
effect with the BDNF locus on recurrent MDD. Our findings
might provide further evidence that the CRHR/BDNF pathway
play an important role in the etiology of recurrent MDD.
In the single-locus evaluation, it was found that the G-allele is
more frequent in the recurrent MDD group than in the control
group, which showed a statistically significant association of SNP
rs242939 (P=0.018) with recurrent MDD. By evaluating
haplotype, rather than single-locus tests of association, the loss of
information attributable to biallelic rather than multiallelic loci
can be compensated, possibly resulting in an increased informa-
tivity. Haplotype analysis revealed that a haplotype of CRHR1had
a highly significant positive association with recurrent MDD, a
haplotype with alleles G-G-T respectively the SNPs of rs1876828,
rs242939, rs242941, was significantly over represented in the
recurrent MDD group than in the control group (chi-2=10.059,
df=1, P=0.016), which suggested that carrying this haplotype
might increase the probability of developing recurrent MDD in
Han Chinese population.
A large amount of literature has focused on studying the genetic
association between the BDNF gene and MDD. However, genetic
association studies of the BDNF rs6265 on MDD have produced
inconsistent results. BDNF polymorphism is associated with
increased risk of depression in some studies [23,24], while some
studies found no association [25,26,27]. In the current study, using
analysis of single loci, we did not find that BDNF rs6265 associated
with recurrent MDD in Han Chinese population. There may be
several interpretations for the discrepancy. Ethnic differences in
polymorphism frequencies might contribute to inconsistent results
in genetic association studies. Furthermore, MDD is a complex
disease that is thought to be caused by multiple genetic factors
each of small effect. Gene–gene interactions are likely to
contribute to the pathophysiology of illness.
Using GMDR analyses, we further inferred the epistatic effects
between CRHR1 and BDNF genes in recurrent MDD. We found
a significant 2-locus (BDNF rs6265 and CRHR1 rs242939) gene–
gene interaction models, which interactions confer an increased
risk for recurrent MDD. Behavioral evidence supports that the
CRHR1/BDNF system is involved in at least certain forms, such
as learning and memory, synaptic plasticity [6]. The finding of
CRHR1/BDNF interactions provides a better understanding of
the genetic mechanisms of recurrent MDD.
Although evidence of a statistical interaction as we report here
does not necessarily map directly onto a biological interaction, true
gene-gene interactions nonetheless must have a biological basis
[28]. Protein encoded by the CRHR1 and BDNF genes work
together to result in lower BDNF in hippocampus. In depressed
patients, a reduced volume of hippocampus has been reported,
and this reduction in volume has been reversed by antidepressants
[19]. There is also large number of studies suggesting a major role
of BDNF in depression. BDNF rs6265 polymorphism is linked to
substantial reduction in the volume of hippocampus, a brain
structure repeatedly associated with the treatment response and
neurogenesis in depression [29]. Our results further contribute to
the hypothesized association between HPA axis dysregulation and
reduced neuroplasticity in depression and are consistent with the
assumption that BDNF is a stress-responsive intercellular messen-
ger modifying HPA axis activity.
One limitation of this study is that the positive finding may be a
result of type I error, but we addressed this limitation by using the
Bonferroni correction. Second, our sample size is relatively small,
however, our study had a power of 0.99 to detect an effect size of
0.5 (moderate) at the 0.05 significance level (2-tailed). Although the
present study is preliminary, we suggested the interactional
association of BDNF and CRHR1 in recurrent MDD should be
replicated in large samples and in the other ethnic populations.
Further work is required to investigate gene-gene interaction
between other genes to progressively elucidate the pathophysiol-
ogy involved in MDD.
Table 2. Haplotype analysis of recurrent MDD patients and
controls.
Haplotype CON (%)
a,b MDD (%)
a,b chi-2 df P -value
GAG 0.66 0.62 1.063 1 0.151
GAT 0.11 0.11 0.001 1 0.542
AAG 0.13 0.09 2.423 1 0.06
GGT 0.08 0.16 10.509 1 0.003
c
Total 13.104 3 0.016
c
aHaplotype frequencies (%) estimation using the EM algorithm from Arlequin.
bAll haplotypes estimated to occur with a frequency of at least 1% in MD
patients or controls are represented.
cBold numerals p-values after Bonferroni correction.
doi:10.1371/journal.pone.0028733.t002
Table 3. Best gene–gene interactions models identified by the generalized multifactor dimensionality reduction (GMDR) method.
Locus number Best combination Cross-validation consistency Testing accuracy (%) P-value
2 rs6265, rs242939 10/10 59.16 0.05
a
4 rs6265,rs1876828, rs242939, rs242941 10/10 57.52 0.08
a
aBold numerals p-values after Bonferroni correction.
doi:10.1371/journal.pone.0028733.t003
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Subjects
The patient sample consisted of 181 unrelated Chinese MDD
individuals (male/female: 72/109; mean age: 33.68610.07 years),
who were outpatients and inpatients from the Psychiatric
Department of the Renmin Hospital of Wuhan University. All
patients had at least two well-defined episodes of MDD (average
number: 3.6) as defined by DSM-IV [30]. Patients were
interviewed by trained psychiatrists using the Structured Clinical
Interview for DSM-IV disorders (SCID-I). Severity of depression
was assessed using the 21-item Hamilton Rating Scale for
Depression (HAMD-21) and the Clinical Global Impression Scale
(CGI) [31,32]. Only subjects with a minimum score of 18 on the
HAMD-21 were selected. Patients with severe organic disorders or
who showed comorbidity for other psychiatric disturbances (eg
substance/alcohol dependence, personality disorders, anxiety
disorders and others) were excluded. There were no significant
differences concerning all other investigated variables (age, clinical
variables such as CGI and HAMD-21 scores) in males and
females.
A total of 186 (male/female: 71/115; mean age: 32.94611.32
years) healthy controls whose age, gender, and ethnically matched
subjects were selected from the general population (Table 4). All
patients and controls were Han people who came from the same
geographical region in China. The Medical Ethics Committees of
the Renmin Hospital of Wuhan University approved the research
project. Patients were included in the study after they gave written
informed consent.
Genotyping
Genomic DNA was extracted from EDTA-anticoagulated
venous blood samples which were carried out as described by
Miller et al [33]. In this study, four single-nucleotide polymor-
phisms (SNPs) were assayed corresponding to the following dbSNP
identifiers: rs1876828, rs242939 and rs242941 (CRHR1 gene),
rs6265 (BDNF gene). SNPs were genotyped with TaqMan
technology (Assay-by-Design) on an ABI 7900 system (Applied
Biosystems). All MGB TaqMan probes and PCR primers were
designed by Applied Biosystems (Foster City, CA, USA). The
standard PCR reaction was carried out using TaqManR Universal
PCR Master Mix reagent kit in a 5 ml volume. Fluorescence data
files from each plate were analyzed by using automated software
(SDS 2.1; Applied Biosystems). All laboratory procedures were
carried out blind to case–control status.
Statistical analysis
The GENEPOP program was used to compare the overall allele
and genotype distributions for each SNP in MDD patients and
controls, and to test Hardy–Weinberg equilibrium [34]. Haplo-
types frequencies in recurrent MD patients and controls were
estimated using the EM algorithm embedded in the program
Arlequin [35]. A total of 10,000 permutation tests were performed
in each analysis. Bonferroni correction was used for multiple
testing, using the total number of SNPs as correction factor. The
GMDR analysis was used to assess gene–gene interactions [36].
We reduced the n-dimensional space formed by a given set of
SNPs to a single dimension to analyze n-way interactions. We
calculated score-based statistics using maximum-likelihood esti-
mates to classify multifactor cells into two different groups (either
high risk or low risk). This was performed for all possible
combinations of SNPs, and the combination with the lowest
misclassification error was selected. Moreover, we tested all
possible 2-locus to 4-locus interactions using 10-fold cross-
validation (CV) in an exhaustive search, which considers all
possible SNP combinations. In addition, we performed logistic
regression models to confirm the results from GMDR analyses.
Power analysis for case-control samples was carried out by
G*Power program (alpha has been set at 0.05).
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